Research Article

Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain

Table 3

Secondary hormonal treatment approaches ().

Value

Antiandrogen withdrawal; (%)99 (56.9)

LHRH agonists; (%)59 (33.9)
 Continue the patient on initial LHRH agonist51 (86.4)
 Switch to a different LHRH agonist8 (13.6)

Addition of antiandrogens; (%)47 (27.0)
 Nonsteroidal antiandrogens41 (87.2)
 Steroidal antiandrogens6 (12.8)

Adrenal testosterone inhibitors; (%)26 (14.9)
 Ketoconazole21 (84.0)
 Corticoids4 (16.0)

Continue the patient on initial treatment; (%)25 (14.4)

Antiandrogen replacement; (%)12 (6.9)
 Nonsteroids 8 (66.7)
 Steroids 4 (33.3)

Estrogenic compounds8 (4.6)

Data are expressed as (percentage of total second hormonal manipulation and option used). Percentages may add up more than 100% as patients could receive more than one hormonal manipulation. LHRH: luteinising hormone-releasing hormone. One missing data.